In a significant stride towards revolutionizing cardiac surgery, medtech innovator Protembis announces a triumphant €30 million Series B funding round. This infusion of capital aims to propel the enrollment of their groundbreaking PROTEMBO Investigational Device in pivotal clinical trials, heralding a new era in brain protection during left-sided heart procedures.
Protembis emerges as a beacon of hope for patients undergoing left-sided heart surgery, vulnerable to the perilous consequences of cerebral injury. The PROTEMBO Investigational Device stands as a formidable shield, safeguarding against ischemic burden – a grave threat encompassing cognitive decline, dementia, and strokes. Notably, the device's efficacy shines during transcatheter aortic valve replacement (TAVR), where its catheter-based system adeptly deflects embolic material away from cerebral circulation, offering a lifeline to countless individuals.
The culmination of 20 successful clinical implementations in their European regulatory study in 2023 serves as a testament to Protembis' unwavering commitment to innovation and patient well-being. With a strategic focus on extending protection to younger patients, the company charts a course towards addressing a critical unmet need in the realm of cardiovascular care.
The Series B funding round, co-led by esteemed European venture capital entities including Segulah Medical Acceleration, XGEN Venture, and TechVision Fund, underscores the profound confidence in Protembis' transformative vision. Noteworthy participation from Coparion, prominent family offices, and angel investors further solidifies the company's position as a trailblazer in medtech innovation.
In a strategic coup, Protembis welcomes the esteemed Dr. Keith D. Dawkins to its board of directors. Dr. Dawkins' illustrious career as a pioneering interventional cardiologist, coupled with his research acumen honed at prestigious institutions such as Stanford University, augments Protembis' wealth of expertise. His appointment marks a pivotal moment in the company's journey, heralding an era of unparalleled growth and advancement.
The infusion of €30 million in Series B funding not only fortifies Protembis' position as a leader in medtech innovation but also signifies a monumental leap towards enhancing patient outcomes in cardiovascular surgery. With the esteemed Dr. Dawkins at the helm, Protembis embarks on a journey brimming with promise and potential, poised to redefine the landscape of cerebral embolic protection. As the company's revolutionary device paves the way for transformative transcatheter therapies, the future of cardiac surgery shines brighter than ever before.
Protembis emerges as a beacon of hope for patients undergoing left-sided heart surgery, vulnerable to the perilous consequences of cerebral injury. The PROTEMBO Investigational Device stands as a formidable shield, safeguarding against ischemic burden – a grave threat encompassing cognitive decline, dementia, and strokes. Notably, the device's efficacy shines during transcatheter aortic valve replacement (TAVR), where its catheter-based system adeptly deflects embolic material away from cerebral circulation, offering a lifeline to countless individuals.
The culmination of 20 successful clinical implementations in their European regulatory study in 2023 serves as a testament to Protembis' unwavering commitment to innovation and patient well-being. With a strategic focus on extending protection to younger patients, the company charts a course towards addressing a critical unmet need in the realm of cardiovascular care.
The Series B funding round, co-led by esteemed European venture capital entities including Segulah Medical Acceleration, XGEN Venture, and TechVision Fund, underscores the profound confidence in Protembis' transformative vision. Noteworthy participation from Coparion, prominent family offices, and angel investors further solidifies the company's position as a trailblazer in medtech innovation.
In a strategic coup, Protembis welcomes the esteemed Dr. Keith D. Dawkins to its board of directors. Dr. Dawkins' illustrious career as a pioneering interventional cardiologist, coupled with his research acumen honed at prestigious institutions such as Stanford University, augments Protembis' wealth of expertise. His appointment marks a pivotal moment in the company's journey, heralding an era of unparalleled growth and advancement.
The infusion of €30 million in Series B funding not only fortifies Protembis' position as a leader in medtech innovation but also signifies a monumental leap towards enhancing patient outcomes in cardiovascular surgery. With the esteemed Dr. Dawkins at the helm, Protembis embarks on a journey brimming with promise and potential, poised to redefine the landscape of cerebral embolic protection. As the company's revolutionary device paves the way for transformative transcatheter therapies, the future of cardiac surgery shines brighter than ever before.
